Dr Paul Arundel
Consultant in Paediatric Metabolic Bone Disease, Sheffield Children’s NHS Foundation Trust
Paediatric bone diseases – improving phenotyping, management and outcomes
Dr Paul Arundel is the Clinical Lead for the Paediatric Metabolic Bone Disease Service at Sheffield Children’s Hospital. His work encompasses the delivery and improvement of care to children and young people with a wide range of bone diseases through collaboration and multidisciplinary team working. He enjoys close links with co-located specialist orthopaedic, spinal, neurosurgical, genetics and radiological services. Links with the Mellanby Centre for Bone Research and INSIGNEO in Sheffield allow translation of basic science advances into novel therapeutic interventions at all ages from infancy through to young adulthood.
He has worked in Sheffield alongside Professor Nick Bishop in both a clinical and research capacity since 2007, following completion of his sub-specialist training in paediatric endocrinology and diabetes. Since 2010 he has been a full-time research-active NHS consultant. He jointly led the implementation of the nationally commissioned Highly Specialised Service for Children with Severe, Complex and Atypical Osteogenesis Imperfecta and maintains close links with the other three nationally-commissioned centres. He is a member and former secretary (2011-2014) of the British Paediatric and Adolescent Bone Group, a network which includes most of the clinicians and researchers from across the British Isles with an interest in children’s bone disease and health. He is on the National Osteoporosis Society’s Vitamin D Working Group.
Within Sheffield, he works as part of a group which has expertise in the phenotyping of children with bone fragility at multiple levels including clinical assessment, functional assessment, use of biochemical and imaging biomarkers, bone tissue assessment using histological and microindentation-based approaches. He has been a sub-investigator on clinical trials of both licensed and novel interventions including risedronate, anti-RANK ligand antibody and recombinant alkaline phosphatase. He was part of the task force developing the International Society for Clinical Densitometry Pediatric Position Statements on the definition of osteoporosis and prediction of fracture risk. Clinical activity and interests extend into the full range of skeletal disorders in childhood including:
- Osteogenesis imperfecta and other inherited forms of bone fragility
- Secondary osteoporosis
- Achondroplasia and other skeletal dysplasias
- Vitamin D
- Disorders of calcium and phosphate metabolism including X-linked hypophosphataemic rickets
- Polyostotic fibrous dysplasia and McCune Albright Syndrome